News & Events

News


Monday May 20, 2019

Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life

- Nearly 30% of Patients with Possible Tardive Dyskinesia Reported Moderate-to-Extreme Problems Performing Their Usual Activities, Including Work, Housework and Leisure Activities - Almost Half of Patients with Possible Tardive Dyskinesia Experienced Moderate-to-Extreme Anxiety or Depression - New


Thursday May 16, 2019

Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting

- RE-KINECT Analysis Provides Insight into the Impact of Possible Tardive Dyskinesia on Patient Health-Related Quality of Life - New Long-Term Data from the KINECT 4 Study Highlight the Overall Effect of INGREZZA® (valbenazine) Treatment on Abnormal Movements in Patients with Tardive Dyskinesia SAN


Tuesday May 07, 2019

Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019

Live Audio Webcast will be on May 14, 2019 SAN DIEGO , May 7, 2019 /PRNewswire/ --  Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2019 at 10:00 a.m. PT ( 1:00 p.m. ET ) on Tuesday, May 14, 2019 , in Las Vegas .


Monday May 06, 2019

Neurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on Patients

- Mental Health Advocacy Community Recognizes and 25 States Declare Tardive Dyskinesia Awareness Week as Part of Mental Health Month to Raise Prominence of Tardive Dyskinesia and Highlight the Impact on the Lives of Patients - New Survey Results Show that Almost 60% of People Taking Antipsychotics


Sunday May 05, 2019

Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting

- Results Confirm the Posterior Trajectory as an Additional Surgical Delivery Route for VY-AADC in Patients with Parkinson's Disease - Treatment with VY-AADC Improved Good ON Time (ON Time Without Troublesome Dyskinesia) by 1.7 Hours and Reduced OFF Time by 2.2 Hours at 12 Months in Patients with

Events